Corcept Therapeutics Inc (CORT) stock
CORTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 11/30349% above fair value
$72.94−0.77 (-1.04%)
Close on Nov 13, 2026Market cap $7.88BP/E 173.7Yield –
Corcept Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Corcept Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $253.86M, up 1.2% year over year. For fiscal 2025 it was $254.91M, up 3.2% from the year before. Over ten years it grew 32.4% a year on average. The highest annual figure on record is $254.91M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $254.91M | +3.2% |
| FY2024 | Dec 31, 2024 | $246.89M | +33.9% |
| FY2023 | Dec 31, 2023 | $184.35M | +40.7% |
| FY2022 | Dec 31, 2022 | $130.99M | +15.0% |
| FY2021 | Dec 31, 2021 | $113.86M | -0.8% |
| FY2020 | Dec 31, 2020 | $114.76M | +28.9% |
| FY2019 | Dec 31, 2019 | $89.02M | +18.3% |
| FY2018 | Dec 31, 2018 | $75.25M | +86.4% |
| FY2017 | Dec 31, 2017 | $40.38M | +69.3% |
| FY2016 | Dec 31, 2016 | $23.84M | +54.6% |
| FY2015 | Dec 31, 2015 | $15.42M | -16.1% |
| FY2014 | Dec 31, 2014 | $18.37M | -10.2% |
| FY2013 | Dec 31, 2013 | $20.47M | +45.4% |
| FY2012 | Dec 31, 2012 | $14.07M | -33.0% |
| FY2011 | Dec 31, 2011 | $21.00M | +10.8% |
| FY2010 | Dec 31, 2010 | $18.95M | +31.6% |
| FY2009 | Dec 31, 2009 | $14.40M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $53.89M | -10.9% |
| Q1 FY2026 | Mar 31, 2026 | $66.27M | +9.1% |
| Q4 FY2025 | Dec 31, 2025 | $64.86M | -7.7% |
| Q3 FY2025 | Sep 30, 2025 | $68.85M | +16.0% |
| Q2 FY2025 | Jun 30, 2025 | $60.47M | +2.9% |
| Q1 FY2025 | Mar 31, 2025 | $60.74M | +3.8% |
| Q4 FY2024 | Dec 31, 2024 | $70.30M | +28.5% |
| Q3 FY2024 | Sep 30, 2024 | $59.34M | +30.4% |
| Q2 FY2024 | Jun 30, 2024 | $58.75M | +35.7% |
| Q1 FY2024 | Mar 31, 2024 | $58.51M | +43.2% |
| Q4 FY2023 | Dec 31, 2023 | $54.71M | +48.8% |
| Q3 FY2023 | Sep 30, 2023 | $45.52M | +36.7% |
| Q2 FY2023 | Jun 30, 2023 | $43.28M | +31.8% |
| Q1 FY2023 | Mar 31, 2023 | $40.85M | +45.3% |
| Q4 FY2022 | Dec 31, 2022 | $36.75M | +28.9% |
| Q3 FY2022 | Sep 30, 2022 | $33.29M | +18.5% |
| Q2 FY2022 | Jun 30, 2022 | $32.83M | +16.3% |
| Q1 FY2022 | Mar 31, 2022 | $28.12M | -3.1% |
| Q4 FY2021 | Dec 31, 2021 | $28.52M | +0.9% |
| Q3 FY2021 | Sep 30, 2021 | $28.09M | -17.1% |
| Q2 FY2021 | Jun 30, 2021 | $28.23M | +6.5% |
| Q1 FY2021 | Mar 31, 2021 | $29.02M | +11.1% |
| Q4 FY2020 | Dec 31, 2020 | $28.28M | +16.3% |
| Q3 FY2020 | Sep 30, 2020 | $33.87M | +48.5% |
| Q2 FY2020 | Jun 30, 2020 | $26.50M | +22.4% |
| Q1 FY2020 | Mar 31, 2020 | $26.12M | +29.0% |
| Q4 FY2019 | Dec 31, 2019 | $24.31M | +29.4% |
| Q3 FY2019 | Sep 30, 2019 | $22.81M | +20.9% |
| Q2 FY2019 | Jun 30, 2019 | $21.66M | +5.4% |
| Q1 FY2019 | Mar 31, 2019 | $20.24M | +18.7% |
| Q4 FY2018 | Dec 31, 2018 | $18.79M | +37.9% |
| Q3 FY2018 | Sep 30, 2018 | $18.86M | +61.3% |
| Q2 FY2018 | Jun 30, 2018 | $20.54M | +160.8% |
| Q1 FY2018 | Mar 31, 2018 | $17.05M | +137.6% |
| Q4 FY2017 | Dec 31, 2017 | $13.63M | +110.2% |
| Q3 FY2017 | Sep 30, 2017 | $11.69M | +65.8% |
| Q2 FY2017 | Jun 30, 2017 | $7.88M | – |
| Q1 FY2017 | Mar 31, 2017 | $7.18M | – |
| Q4 FY2016 | Dec 31, 2016 | $6.48M | – |
| Q3 FY2016 | Sep 30, 2016 | $7.05M | – |
See a number that looks wrong?